Strategy and Portfolio Update GUILFORD, Conn., March 30, 2017 – LAM Therapeutics, a 4Catalyzer company that develops drugs for cancer and rare diseases, announced that it has closed $58M in Series C financing. 4Catalyzer is Connecticut’s premier biotechnology incubator and has raised over a quarter billion dollars to support its current class of startups. LAM […]
LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and rare diseases. LAM accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics, and combinational drug screening, with deep learning to match clinical drugs to new indications. LAM has advanced two drugs into clinical trials: LAM-001 for lymphangioleiomyomatosis, LAM-002 for B-cell non-Hodgkin lymphoma, and is preparing to advance LAM-003 into the clinic for hematological malignancies.
LAM-001, inhaled mTOR kinase Inhibitor
Hyperactivation of mTOR signaling is a central driver in the genetic-based disease lymphangioleiomyomatosis . LAM Therapeutics has completed the Phase 1 trial of its inhaled mTOR inhibitor developed to treat lymphangioleimyomatosis.
LAM-002, PIKfyve kinase inhibitor
LAM-002 is an exquisitely selective first-in-class PIKfyve kinase inhibitor that is cytotoxic for specific cancers with little to no effect on normal cells. LAM Therapeutics advanced LAM-002 into a Phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma within one year of discovery.
LAM-002 is also being evaluated in pre-clinical models of neurological disease.
LAM-003 is an orally active, small-molecule, immune-modulating, anti-cancer drug. The drug has completed a Phase 1 clinical trial and will now be tested in hematological malignancies as a single agent and in combination therapy.
LAM Therapeutics is actively applying its technologies to advance discovery of clinical stage drugs for immuno-oncology and rare disease indications.
Learn more about LAM Therapeutics clinical trials >
View LAM Therapeutics publications>
LAM accelerates drug development by deploying technologies including genome editing, chemical genomics, artificial intelligence (AI) and combinational drug screening to match clinical drugs to new indications.
LAM’s virtuous circle strategy integrates patient data, AI, and next-gen sequencing. We test LAM drugs in clinical trials, and then analyze genomics and proteomics data to match drugs to patients. Our deep learning AI technology gets smarter with each patient treated and more data analyzed, which helps us select the most appropriate patients to treat.
LAM Therapeutics is a fully-funded startup dedicated to developing breakthrough therapeutics for the treatment of rare diseases and cancer.
Working with proprietary technologies, LAM Therapeutics is making a difference. The company is privately funded, allowing you to focus 100% on doing the best science of your life.
Join a world-class team in developing the next-generation of breakthrough drugs. LAM Therapeutics is seeking extraordinary gifted and driven scientists, with a track record of success developing, implementing and scaling up new technologies.
NOTES TO RECRUITERS
The Company does not accept resumes submitted by, or candidates referred from, external agencies by any means (including but not limited to via the Internet, email, fax, U.S. mail and/or verbal communications). Any third-party resume forwarded by such recruiters will be treated as a direct application and shall be deemed to be the property of the Company, and the Company reserves the right to contact the candidate directly and the recruiter will not receive any compensation from the Company.
Bringing the total raised for the current class of 4Catalyzer companies to a quarter-billion dollars GUILFORD, Conn. –Feb. 2, 2016– LAM Therapeutics closed a $40 million financing to accelerate the development of therapeutics for the treatment of rare diseases and cancer. LAM Therapeutics is a 4Catalyzer company. 4Catalyzer is Connecticut’s premier biotechnology startup incubator and […]
Company is first to focus on developing drugs for Lymphangioleiomyomatosis Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds from the financing will […]